April 22, 2024

Webinar: Advancing in vitro high-throughput transcriptomics for chemical toxicity testing

Webinar: Advancing in vitro high-throughput transcriptomics for chemical toxicity testing
About this webinar

Toxicity testing is on the cusp of transitioning away from expensive and ethically challenged animal-based methods, towards more efficient alternative approaches. Concurrently, advances in technologies that examine sub-lethal effects on gene expression have led to increased interest in the concept of transcriptomic points of departure (tPODs), or the threshold concentration beyond which a concerted response in gene expression may be expected, indicating the potential for adverse effects at the organismal level.

These concentrations have been found to be lower than (i.e. protective of) benchmark effect concentrations that can cause mortality and reproductive defects. Consequentially, there is growing scientific and regulatory interest in tPODs for applications in chemical screening and prioritization.

Hear from researchers from McGill University, as they present case studies in optimizing and advancing efficient workflows that couple in vitro exposures with ultraplexed library preparation using the QIAseq UPXome RNA Library Kit. This approach has increased the throughput of differential expression and dose-response analysis for tPODs derivation.

Additionally, learn how combining ultraplexed library preparation with mosquito® automated liquid handling has improved efficiency in two ways:

  • Shortening the overall library preparation protocol time
  • Reducing reagent usage by a half by miniaturizing protocol volumes
register now

Our latest News

discover more
New approach for T-cell immunotherapy against malignant brain tumors

New approach for T-cell immunotherapy against malignant brain tumors

Researchers at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM) have developed a promising cellular immunotherapy for the treatment of glioblastomas: They equipped T cells with a receptor that recognizes a protein of the brain tumors that is responsible for the dangerous stem cell properties. The therapeutic T cells directed […]

RNA Origami: Artificial Cytoskeletons to Build Synthetic Cells

RNA Origami: Artificial Cytoskeletons to Build Synthetic Cells

Synthetic biologists from Heidelberg University create nanotubes folded from the natural RNA biomolecule With the long-term goal of creating living cells from non-living components, scientists in the field of synthetic biology work with RNA origami. This tool uses the multifunctionality of the natural RNA biomolecule to fold new building blocks, making protein synthesis superfluous. In […]

Hummingbird Diagnostics Announces Publication Evaluating miR-Blood’s Small RNA Expression Dataset Capabilities in Nature’s Scientific Data

Hummingbird Diagnostics Announces Publication Evaluating miR-Blood’s Small RNA Expression Dataset Capabilities in Nature’s Scientific Data

miR-Blood is capable of revealing highly cell-type specific patterns of small RNA expression HEIDELBERG, Germany, March 06, 2024 – Hummingbird Diagnostics GmbH, a leader in using blood-based small RNAs for early disease detection and characterization, today announced a publication in Scientific Data, a peer-reviewed, open-access journal launched by Nature. The study evaluated miR-Blood, Hummingbird Diagnostics’ […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp